Dra. María Natalia Gandur Quiroga, Coordinator in charge of the Urology Clinic Service at the Angel H. Roffo Institute, shared a post on X:
“Amazing session by Bertrand Tombal at PROSCA24. Key takeaways from EMBARK.
- EMBARK redefines BCR: Adding enzalutamide + ADT significantly improves metastasis-free survival (MFS) and overall survival (OS).
- Patient benefits: Enzalutamide monotherapy shows significant MFS improvement over ADT alone, paving the way for its role as systemic therapy.
- AE Profile: Combination of enzalutamide and ADT increases grade ≥3 adverse events (31.3%) but remains manageable.
- High-risk outcomes: Patients with PSA doubling ≤9 months benefit most.
- Post hoc insights: Sexual activity-related quality of life remains comparable with delayed TTCD in enzalutamide monotherapy.
Is it still acceptable to delay enzalutamide initiation in EMBARK patients?”
For more updates, follow OncoDaily.
